专题：Lymphoma Diagnosis and Treatment

This cluster of papers focuses on the classification, molecular profiling, genetic pathogenesis, and treatment strategies for various types of lymphoid neoplasms, including Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma. It also explores the use of PET imaging, rituximab therapy, and gene expression profiling to predict survival and guide treatment decisions.
最新文献
First-line treatment for CLL in the era of targeted therapy

article Full Text OpenAlex

T-cell engaging antibodies for B-cell lymphomas

article Full Text OpenAlex

Structure-guided Genome-wide Association Analysis of ALK Variants with GWAS Data Using R

article Full Text OpenAlex

Recent trends of incidence and mortality of cutaneous lymphomas in Germany

article Full Text OpenAlex

Integrated QSAR, docking, pharmacokinetics, and molecular dynamics approaches for designing IRAK4 inhibitors against MYD88^L265P-driven diffuse large B-cell lymphoma

article Full Text OpenAlex

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

article Full Text OpenAlex

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

article Full Text OpenAlex

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

article Full Text OpenAlex

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

article Full Text OpenAlex

Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib

article Full Text OpenAlex

近5年高被引文献
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

review Full Text OpenAlex 3434 FWCI472.0193

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

article Full Text OpenAlex 2461 FWCI374.646

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

article Full Text OpenAlex 1374 FWCI189.5902

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

article Full Text OpenAlex 757 FWCI115.9485

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

article Full Text OpenAlex 713 FWCI71.3642

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

article Full Text OpenAlex 637 FWCI191.2612

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

article Full Text OpenAlex 618 FWCI60.1833

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

article Full Text OpenAlex 491 FWCI48.2388

Epstein-Barr virus: Biology and clinical disease

review Full Text OpenAlex 488 FWCI46.9832

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

article Full Text OpenAlex 423 FWCI59.3656